NO2964638T3 - - Google Patents

Info

Publication number
NO2964638T3
NO2964638T3 NO14710620A NO14710620A NO2964638T3 NO 2964638 T3 NO2964638 T3 NO 2964638T3 NO 14710620 A NO14710620 A NO 14710620A NO 14710620 A NO14710620 A NO 14710620A NO 2964638 T3 NO2964638 T3 NO 2964638T3
Authority
NO
Norway
Application number
NO14710620A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2964638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2964638T3 publication Critical patent/NO2964638T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO14710620A 2013-03-06 2014-03-05 NO2964638T3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06
PCT/GB2014/050655 WO2014135876A1 (en) 2013-03-06 2014-03-05 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Publications (1)

Publication Number Publication Date
NO2964638T3 true NO2964638T3 (cs) 2018-01-06

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14710620A NO2964638T3 (cs) 2013-03-06 2014-03-05

Country Status (42)

Country Link
US (4) US9066979B2 (cs)
EP (2) EP3342770B1 (cs)
JP (1) JP5894714B1 (cs)
KR (1) KR101645112B1 (cs)
CN (1) CN105209456B (cs)
AP (1) AP2015008696A0 (cs)
AR (1) AR095039A1 (cs)
AU (1) AU2014224382B2 (cs)
BR (1) BR112015020787B1 (cs)
CA (1) CA2901269C (cs)
CL (1) CL2015002361A1 (cs)
CR (1) CR20150450A (cs)
CY (1) CY1119487T1 (cs)
DK (1) DK2964638T3 (cs)
DO (1) DOP2015000189A (cs)
ES (1) ES2642201T3 (cs)
GT (1) GT201500251A (cs)
HR (1) HRP20171689T1 (cs)
HU (1) HUE034568T2 (cs)
IL (1) IL240578B (cs)
LT (1) LT2964638T (cs)
MA (1) MA38380A1 (cs)
ME (1) ME03041B (cs)
MX (1) MX362247B (cs)
MY (1) MY186126A (cs)
NI (1) NI201500123A (cs)
NO (1) NO2964638T3 (cs)
PE (1) PE20152000A1 (cs)
PH (1) PH12015501965B1 (cs)
PL (1) PL2964638T3 (cs)
PT (1) PT2964638T (cs)
RS (1) RS56566B1 (cs)
RU (1) RU2656597C2 (cs)
SG (1) SG11201506487YA (cs)
SI (1) SI2964638T1 (cs)
SM (1) SMT201700542T1 (cs)
TN (1) TN2015000368A1 (cs)
TW (1) TWI543977B (cs)
UA (1) UA115686C2 (cs)
UY (1) UY35369A (cs)
WO (1) WO2014135876A1 (cs)
ZA (1) ZA201507353B (cs)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2964638T3 (cs) * 2013-03-06 2018-01-06
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
EP3201190A4 (en) 2014-10-01 2018-03-14 Sun Pharmaceutical Industries Ltd Crystalline form of afatinib dimaleate
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105859641B (zh) 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物a晶型及其制备方法
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物b晶型及其制备方法
AU2017312561B2 (en) 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
WO2019157225A2 (en) * 2018-02-08 2019-08-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
SG11202101712XA (en) 2018-09-14 2021-04-29 Spectrum Pharmaceuticals Inc Kits and methods for treating cancers
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
CN113439080B (zh) 2019-02-02 2022-12-20 上海复星医药产业发展有限公司 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
KR20210144844A (ko) 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
CR20210624A (es) 2019-06-21 2022-02-14 Hoffmann La Roche Inhibidor de egfr para el tratamiento de cáncer
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
EP4499102A1 (en) 2022-03-31 2025-02-05 Astrazeneca AB Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
KR20250006237A (ko) 2022-04-28 2025-01-10 아스트라제네카 아베 축합 바이사이클릭 헤테로방향족 화합물 및 암의 치료에서의 이의 용도
CN119421895A (zh) 2022-06-27 2025-02-11 阿斯利康(瑞典)有限公司 涉及用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂的组合
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
IL318241A (en) 2022-07-08 2025-03-01 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
WO2024178124A2 (en) * 2023-02-21 2024-08-29 Prosetta Biosciences, Inc. Quinazoline compounds and uses
CN118063441B (zh) * 2024-02-03 2025-09-19 四川大学华西医院 一种氨基喹唑啉类化合物的制备及抗肿瘤作用
CN119192146B (zh) * 2024-08-16 2025-08-29 安徽法尔麦斯生物科技有限公司 一种抑制剂化合物及应用和治疗癌症的药物
CN119912429B (zh) * 2025-01-21 2025-11-04 安徽医科大学 一类具有抗炎活性的喹唑啉类化合物或其药学上可接受的盐、药物组合物及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
PT1060247E (pt) 1998-02-24 2008-12-22 Sisters Of Providence In Orego Composições que contêm um agente de ligação ao receptor ox-40 ou um ácido nucleico que codifica para o mesmo e métodos para melhorar a resposta imunitária específica do antigénio
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
BR0014133A (pt) 1999-09-21 2002-06-11 Astrazeneca Ab Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
IL164167A0 (en) * 2002-03-30 2005-12-18 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines/ quinolines as tyrosine kinase inhibitors
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
BRPI0413066A (pt) 2003-07-29 2006-10-17 Astrazeneca Ab derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
MXPA06003161A (es) 2003-09-16 2006-06-05 Astrazeneca Ab Derivados de quinazolina.
ES2281007T3 (es) 2003-09-19 2007-09-16 Astrazeneca Ab Derivados de quinazolina.
HRP20070113T3 (en) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazoline derivatives
BRPI0508286B8 (pt) 2004-03-31 2021-05-25 Dana Farber Cancer Inst Inc método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN101175734B (zh) 2005-05-12 2011-10-12 黄文林 一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
WO2006119673A1 (fr) * 2005-05-12 2006-11-16 Wenlin Huang Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
CA2619037A1 (en) 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
SI1971601T1 (sl) * 2005-11-15 2010-03-31 Array Biopharma Inc N fenil kinazolin aminski derivati in sorodne spojine kot inhibitorji ERBB tip I receptorske tirozin kinaze za zdravljenje hiperproliferativnih bolezni
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (en) 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
TW202517680A (zh) 2008-12-09 2025-05-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
SI2504364T1 (sl) 2009-11-24 2017-11-30 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
HRP20221090T1 (hr) 2009-12-31 2022-11-25 Hutchison Medipharma Limited Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
ES2630328T3 (es) 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
NO2964638T3 (cs) * 2013-03-06 2018-01-06

Also Published As

Publication number Publication date
MX2015011818A (es) 2016-01-08
HUE034568T2 (en) 2018-02-28
AR095039A1 (es) 2015-09-16
GT201500251A (es) 2017-10-09
PH12015501965B1 (en) 2021-08-04
US9375432B2 (en) 2016-06-28
UA115686C2 (uk) 2017-12-11
DOP2015000189A (es) 2015-08-31
BR112015020787B1 (pt) 2022-12-06
CA2901269A1 (en) 2014-09-12
ME03041B (me) 2018-10-20
CN105209456B (zh) 2018-05-08
RS56566B1 (sr) 2018-02-28
EP2964638B1 (en) 2017-08-09
PL2964638T3 (pl) 2018-01-31
PH12015501965A1 (en) 2016-01-11
KR20150083782A (ko) 2015-07-20
HRP20171689T1 (hr) 2018-02-23
BR112015020787A2 (pt) 2017-07-18
US20150320751A1 (en) 2015-11-12
JP5894714B1 (ja) 2016-03-30
WO2014135876A1 (en) 2014-09-12
JP2016511225A (ja) 2016-04-14
ES2642201T3 (es) 2017-11-15
AP2015008696A0 (en) 2015-08-31
MA38380A1 (fr) 2017-01-31
NI201500123A (es) 2016-02-16
US9066979B2 (en) 2015-06-30
PE20152000A1 (es) 2016-01-22
EP3342770B1 (en) 2022-03-30
CA2901269C (en) 2022-01-18
US20180016259A1 (en) 2018-01-18
PT2964638T (pt) 2017-11-14
MX362247B (es) 2019-01-09
CN105209456A (zh) 2015-12-30
SI2964638T1 (sl) 2017-11-30
US20160340342A1 (en) 2016-11-24
IL240578A0 (en) 2015-09-24
SMT201700542T1 (it) 2018-01-11
AU2014224382A1 (en) 2015-09-03
EP2964638A1 (en) 2016-01-13
HK1216315A1 (en) 2016-11-04
CL2015002361A1 (es) 2016-01-04
UY35369A (es) 2014-08-29
TW201520206A (zh) 2015-06-01
LT2964638T (lt) 2017-12-27
CY1119487T1 (el) 2018-03-07
ZA201507353B (en) 2017-03-29
NZ710850A (en) 2020-09-25
DK2964638T3 (en) 2017-10-30
KR101645112B1 (ko) 2016-08-02
MY186126A (en) 2021-06-24
RU2015139513A (ru) 2017-04-10
US9718806B2 (en) 2017-08-01
CR20150450A (es) 2015-12-01
EP3342770A1 (en) 2018-07-04
TN2015000368A1 (en) 2017-01-03
TWI543977B (zh) 2016-08-01
IL240578B (en) 2019-03-31
AU2014224382B2 (en) 2016-11-10
RU2656597C2 (ru) 2018-06-06
US20140255428A1 (en) 2014-09-11
SG11201506487YA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cs)
BR112015007533A2 (cs)
BR102016010778A2 (cs)
BR112014017733A2 (cs)
BR112014018502A2 (cs)
BR112014017739A2 (cs)
BR112014019326A2 (cs)
BR112014018480A2 (cs)
BR112014018516A2 (cs)
BR112014020341A2 (cs)
BR112014017855A2 (cs)
BR112014017765A2 (cs)
BR112014017669A2 (cs)
BR112014021878A2 (cs)
BR112014018468A2 (cs)
BR112014017901A2 (cs)
BR112014019204A2 (cs)
BR112014018207A2 (cs)
BR112015015948A2 (cs)
BR112014017722A2 (cs)
BR112014017653A2 (cs)
BR112016000485A2 (cs)
BR112014018578A2 (cs)
BR112014018483A2 (cs)
BR112014017794A2 (cs)